Company Filing History:

11 out of 6,850

Ciba-geigy Corporation

patents

where one patent can have more than one assignee

Years Active: 1980-2002

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6342373 - Process for preparing recombinant eglin, protease inhibitor (2002-01-29),

2. 5728549 - Process for the manufacture of thrombin inhibitors (1998-03-17),

3. 5686564 - Peptide derivatives corresponding to the carboxy terminal sequence of (1997-11-11),

4. 5422249 - Process for the manufacture of thrombin inhibitors (1995-06-06),

5. 5354843 - Flanking peptides of calcitonin and processes for their manufacture (1994-10-11),

6. 5093530 - 2,4-dimethoxy-4'-hydroxy-benzophenone (1992-03-03),

7. 5004781 - Synthetic polystyrene resin and its use in solid phase peptide synthesis (1991-04-02),

8. 4859736 - Synthetic polystyrene resin and its use in solid phase peptide synthesis (1989-08-22),

9. 4720483 - Oligopeptides and intermediates and processes for their manufacture (1988-01-19),

10. 4369179 - Acylpeptides (1983-01-18),

11. 4358439 - Cyclooctapeptides (1982-11-09),

12. 4328214 - Cyclopeptides and pharmaceutical preparations thereof and also processes (1982-05-04),

13. 4316890 - Peptides and processes for the manufacture thereof (1982-02-23),

14. 4238481 - Novel cyclopeptides (1980-12-09),

Title: The Innovative Contributions of Hans Rink

Introduction

Hans Rink, an esteemed inventor based in Riehen, Switzerland, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 14 patents, his innovations primarily revolve around pharmaceutical applications that leverage genetic engineering techniques.

Latest Patents

Among his notable inventions is a process for preparing recombinant eglin, a protease inhibitor. This invention is crucial as it relates to DNA sequences coding for eglin, expression plasmids, and hosts transformed with these plasmids. The resulting eglin compounds exhibit beneficial pharmacological properties. Another significant patent is focused on the manufacture of thrombin inhibitors. It includes DNA sequences for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors, and transformed host cells. The hirudin compounds produced through this process also exhibit valuable pharmacological properties, showcasing Rink's expertise in therapeutic innovations.

Career Highlights

Hans Rink has had a prolific career, working with renowned companies in the pharmaceutical sector. He has been associated with Ciba-Geigy Corporation and Novartis Corporation, where his work contributed to the advancement of biopharmaceuticals and therapeutics.

Collaborations

Throughout his career, Rink has collaborated with notable colleagues such as Peter Sieber and Bruno Kamber. These collaborations have undoubtedly enriched his work and enabled the development of innovative solutions in biotechnology.

Conclusion

Hans Rink's contributions to the field of biotechnology through his inventive processes have provided valuable advancements in drug development. His work continues to influence the pharmaceutical industry, showcasing the importance of innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com